Patient monitoring

How it works
Masimo
rainbow SET™ technology

Masimo rainbow SET technology expands the capabilities of Philips lntelliVue patient monitors. Masimo rainbow SET is a non-invasive measurement platform that incorporates motion and low perfusionTM pulse oximetry.

Standard parameters

Masimo set pulse oximetry
Masimo SET™ pulse oximetry
pulse rate
Pulse rate
perfusion index
Perfusion Index

Optional parameters

Pleth variability index
Pleth Variability Index
Standard parameter
Total hemoglobin
Standard parameter
Methemoglobin saturation
Standard parameter
Carboxyhemoglobin
Standard parameter
Acoustic Respiration rate
Standard parameter
Oxygen content

Common measurement parameters

 

SpO2 - measure of oxygen saturation even through motion and low perfusion

 

SpHb1 - provides real-time visibility to changes – or lack of changes – in haemoglobin levels between invasive blood samples

 

PVi - measure of the dynamic changes in the Perfusion Index (PERF) that occur during one or more respiratory cycles

Intuitive display on Masimo measurements on Philips IntelliVue monitors


Clear and intuitive screen displays combine vital signs with Masimo rainbow SET parameters – providing trend data and current data on one easy-to-read screen.

Masimo rainbow SET parameters

Masimo rainbow SET parameters

 

SPO2 non-invasive oxygen saturation

SpHb non-invasive continuous haemoglobin

PVi Pleth Variability index

Pi PERF Perfusion index

SpOC non-invasive oxygen content

SpMet non-invasive methaemoglobin

Masimo rainbow Horizon trends

Horizon trends

 

Horizon trends clearly indicate timely changes in patient condition – to aid you to quickly identify meaningful clinical deviations and take appropriate actions.

Non-invasive rainbow SET technology


Advanced rainbow SET sensors utilise multiple wavelengths of light to measure total haemoglobin (SpHb), Pleth Variability Index (PVi), oxygen content (SpOC). carboxyhaemoglobin (SpCO) and methaemoglobin (SpMet) non-invasively and continuously.
SET Technology

Works with your IT, works for your clinical teams

 

Philips IntelliVue monitoring platform fits securely into your hospital’s IT environment to capture timely patient data and feed it to the EMR. Capitalise on your IT investments, support your care teams with clinically proven solutions – without the need to purchase additional equipment.

 

With more than 1 million monitors sold since 2002, the IntelliVue family of monitoring solutions offers a proven track record for quality.

Non-invasive measurement technology – in clinical practice


Peer reviews have found that using SpHb monitoring in conjunction with invasive blood sampling can deliver value in A&E, OR, and during transport.

Stat icon 1

In low blood loss surgical applications

Reduces unnecessary transfusions

>87% reduction in transfusion frequency

(from 4.5% to 0.6%)2

 

>90% reduction in average units transfused (from 0.1 to 0.01 units per patient)2

Stat icon 2

In high blood loss surgical applications

Reduces unnecessary transfusions

> 73% to 32% reduction in the percentage of patients receiving 3 or more units3*

 

> 47% reduction in average units transfused (1.9 to 1.0 per patient)3*

Initiate timely transfusions when transfusions are needed

Contact information

* This field is mandatory
*

Contact details

*
*
*

Company details

*
*
*
*
*

Business details

By specifying your reason for contact we will be able to provide you with a better service.
*
*

See more about Philips and Masimo

Philips IntelliVue with Rainbow SET

Philips IntelliVue with rainbow SET

 

Versatile platform provides continuous and non-invasive patient monitoring with leading haemoglobin measurement technology.

Philips and Masimo partnership

The partnership

 

Philips and Masimo have teamed up to create the future of measurements and monitoring.

References

 

Masimo clinical claims are referenced on this web page. All studies available at www.masimo.com/evidence/featured-studies/feature/

(1) SpHb** monitoring is not intended to replace lab testing. Blood samples should be analyzed by lab instruments prior to clinical decision making.

(2) Transt. 2014. 5:237.DOl:10.4172/2155-9864.1000237

(3) Awada WN et al J Clin Mon it Comput. DOI 10.1007/s10877-015-9660-4.

*Study Protocol: In each group, if researchers noted SpHb trended downward below 10 g/dl, a red blood cell transfusion was started and continued until SpHb trended upward above 10 g/dl. The transfusion threshold of 10 g/dl was predetermined by the study protocol and may not be appropriate for all patients. Blood sampling was the same for the control and test group. Artertal blood was drawn from a 20 gauge radial.